Quick Answer
MoonLake Immunotherapeutics reported Cash And Cash Equivalents At Carrying Value of $334.52 million for the year ending 2025.
- MoonLake Immunotherapeutics showed an increase of +85.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from MoonLake Immunotherapeutics's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2020: $1.34 million | Q1 2021: $1.17 million | Q2 2021: $1.10 million | Q3 2021: $1.03 million | Q1 2022: $23.3 thousand | Q3 2022: $41.20 million | Q1 2023: $50.13 million | Q2 2023: $501.79 million | Q3 2023: $318.17 million | Q1 2024: $458.44 million | Q2 2024: $342.79 million | Q3 2024: $375.66 million | Q1 2025: $271.57 million | Q2 2025: $306.68 million | Q3 2025: $350.74 million.
- Over the full 6 years of available data (2020 to 2025), MoonLake Immunotherapeutics's Cash And Cash Equivalents At Carrying Value has grown by 24,940.1%.
- Historical annual values: Fiscal year 2025: $334.52 million | Fiscal year 2024: $180.43 million | Fiscal year 2023: $451.17 million | Fiscal year 2022: $39.51 million | Fiscal year 2021: $8.04 million | Fiscal year 2020: $1.34 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: